10% Discount
•
CODE: Perlancia10
•
Third-Party Tested Research Peptides
Perlancia Peptides
Perlancia Peptides restricts purchases to individuals conducting laboratory or institutional research and at least 21 years old. By entering, you confirm you meet this requirement.
All products offered on this website are sold strictly as research chemicals for in-vitro laboratory research use only. They are not drugs, foods, cosmetics, dietary supplements or medical devices, and they are not intended for human or veterinary consumption, diagnostic use, or therapeutic use of any kind.
Selecting “No” will take you away from this website. This confirmation will be remembered on this device for 30 days.
$62.00
629 in stock
CJC-1295 and Ipamorelin are synthetic peptide compounds that have been investigated in laboratory research related to endocrine signaling and peptide receptor activity.
CJC-1295 is a synthetic analog derived from growth hormone–releasing hormone (GHRH) designed for research involving pituitary signaling pathways. Ipamorelin is a pentapeptide analog investigated for its interaction with ghrelin receptor pathways in endocrine research settings.
When studied together in laboratory environments, this peptide combination has been explored in research examining signaling mechanisms involved in growth hormone regulation and receptor-mediated cellular communication.
This compound is supplied as a lyophilized research peptide blend intended for laboratory and analytical research applications.
Laboratory investigations involving CJC-1295 and Ipamorelin have explored several research contexts, including:
These areas of research focus on understanding peptide interactions with hormone-related signaling systems and receptor pathways.
Research has investigated CJC-1295 for its interaction with growth hormone–releasing hormone receptors located within the anterior pituitary signaling network.
Studies have explored how CJC-1295 analogs interact with endocrine regulatory pathways involved in hormone signaling communication between the hypothalamus and pituitary structures.
Ipamorelin has been investigated in laboratory models for its interaction with ghrelin receptor pathways. These receptors are studied in research related to peptide signaling and endocrine communication networks.
Research involving this peptide pairing often examines how distinct receptor pathways may function within broader endocrine signaling systems and peptide hormone regulatory networks.
CJC-1295 was developed as a synthetic analog designed for laboratory studies involving growth hormone–releasing hormone signaling pathways. Early research focused on understanding how modified peptide structures may interact with endocrine receptor networks.
Ipamorelin was later developed as a selective peptide analog studied for its interaction with ghrelin receptor signaling pathways.
Scientific research has explored both peptides independently and in combination to better understand receptor activity, peptide stability, and endocrine signaling communication mechanisms.
Laboratory investigations involving these peptides continue to contribute to broader scientific understanding of peptide hormone analogs and receptor-mediated signaling pathways.
For laboratory stability, lyophilized peptides should be stored in a cool, dry environment prior to reconstitution.
Following reconstitution for research applications, laboratory storage under refrigerated conditions is recommended to maintain peptide stability during experimental use.
Handling should follow standard laboratory research procedures appropriate for peptide compounds.
FOR RESEARCH USE ONLY.
This product is intended strictly for laboratory research purposes. It is not intended for human or veterinary use.
CJC-1295 is a synthetic peptide derived from the growth hormone–releasing hormone (GHRH) family of regulatory peptides. It was developed to investigate how modified peptide structures interact with endocrine signaling pathways associated with pituitary hormone regulation.
Ipamorelin is a synthetic pentapeptide analog studied for its interaction with ghrelin receptor pathways. It belongs to a class of peptides investigated for their role in peptide-mediated endocrine signaling.
Both peptides are commonly examined in research focused on peptide hormone analogs and receptor-mediated signaling networks. Their structural differences allow researchers to study multiple endocrine pathway interactions within laboratory models.
Laboratory investigations have explored how peptide analogs such as CJC-1295 interact with signaling pathways associated with growth hormone regulatory mechanisms.
Ipamorelin has been studied for its interaction with ghrelin receptor signaling pathways, which are part of broader endocrine communication systems studied in laboratory environments.
Synthetic peptide analogs are often investigated to better understand how structural modifications influence receptor interactions, signaling stability, and peptide activity within controlled research models.
Research involving these peptides frequently focuses on the interaction between hypothalamic and pituitary signaling networks involved in hormone communication pathways.
Research has examined how CJC-1295 interacts with growth hormone–releasing hormone receptor pathways in laboratory models of endocrine signaling.
Studies have explored how Ipamorelin interacts with ghrelin receptor pathways involved in peptide-mediated cellular communication.
When studied together, these peptides are sometimes investigated for their roles within broader endocrine signaling networks that regulate hormone communication pathways.
Laboratory investigations continue to explore how different peptide analogs interact with receptor systems involved in endocrine regulation.
Scientific literature surrounding CJC-1295 and Ipamorelin focuses primarily on:
Research in these areas contributes to the broader scientific understanding of peptide-based signaling molecules and their interaction with receptor pathways studied in laboratory environments.
Research involving CJC-1295 and Ipamorelin can be found within scientific literature databases and peer-reviewed journals including:
There are no reviews yet.
Only logged in customers who have purchased this product may leave a review.
CJC-1295 and Ipamorelin are synthetic peptide compounds that have been investigated in laboratory research related to endocrine signaling and peptide receptor activity.
CJC-1295 is a synthetic analog derived from growth hormone–releasing hormone (GHRH) designed for research involving pituitary signaling pathways. Ipamorelin is a pentapeptide analog investigated for its interaction with ghrelin receptor pathways in endocrine research settings.
When studied together in laboratory environments, this peptide combination has been explored in research examining signaling mechanisms involved in growth hormone regulation and receptor-mediated cellular communication.
This compound is supplied as a lyophilized research peptide blend intended for laboratory and analytical research applications.
Laboratory investigations involving CJC-1295 and Ipamorelin have explored several research contexts, including:
These areas of research focus on understanding peptide interactions with hormone-related signaling systems and receptor pathways.
Research has investigated CJC-1295 for its interaction with growth hormone–releasing hormone receptors located within the anterior pituitary signaling network.
Studies have explored how CJC-1295 analogs interact with endocrine regulatory pathways involved in hormone signaling communication between the hypothalamus and pituitary structures.
Ipamorelin has been investigated in laboratory models for its interaction with ghrelin receptor pathways. These receptors are studied in research related to peptide signaling and endocrine communication networks.
Research involving this peptide pairing often examines how distinct receptor pathways may function within broader endocrine signaling systems and peptide hormone regulatory networks.
CJC-1295 was developed as a synthetic analog designed for laboratory studies involving growth hormone–releasing hormone signaling pathways. Early research focused on understanding how modified peptide structures may interact with endocrine receptor networks.
Ipamorelin was later developed as a selective peptide analog studied for its interaction with ghrelin receptor signaling pathways.
Scientific research has explored both peptides independently and in combination to better understand receptor activity, peptide stability, and endocrine signaling communication mechanisms.
Laboratory investigations involving these peptides continue to contribute to broader scientific understanding of peptide hormone analogs and receptor-mediated signaling pathways.
For laboratory stability, lyophilized peptides should be stored in a cool, dry environment prior to reconstitution.
Following reconstitution for research applications, laboratory storage under refrigerated conditions is recommended to maintain peptide stability during experimental use.
Handling should follow standard laboratory research procedures appropriate for peptide compounds.
FOR RESEARCH USE ONLY.
This product is intended strictly for laboratory research purposes. It is not intended for human or veterinary use.
CJC-1295 is a synthetic peptide derived from the growth hormone–releasing hormone (GHRH) family of regulatory peptides. It was developed to investigate how modified peptide structures interact with endocrine signaling pathways associated with pituitary hormone regulation.
Ipamorelin is a synthetic pentapeptide analog studied for its interaction with ghrelin receptor pathways. It belongs to a class of peptides investigated for their role in peptide-mediated endocrine signaling.
Both peptides are commonly examined in research focused on peptide hormone analogs and receptor-mediated signaling networks. Their structural differences allow researchers to study multiple endocrine pathway interactions within laboratory models.
Laboratory investigations have explored how peptide analogs such as CJC-1295 interact with signaling pathways associated with growth hormone regulatory mechanisms.
Ipamorelin has been studied for its interaction with ghrelin receptor signaling pathways, which are part of broader endocrine communication systems studied in laboratory environments.
Synthetic peptide analogs are often investigated to better understand how structural modifications influence receptor interactions, signaling stability, and peptide activity within controlled research models.
Research involving these peptides frequently focuses on the interaction between hypothalamic and pituitary signaling networks involved in hormone communication pathways.
Research has examined how CJC-1295 interacts with growth hormone–releasing hormone receptor pathways in laboratory models of endocrine signaling.
Studies have explored how Ipamorelin interacts with ghrelin receptor pathways involved in peptide-mediated cellular communication.
When studied together, these peptides are sometimes investigated for their roles within broader endocrine signaling networks that regulate hormone communication pathways.
Laboratory investigations continue to explore how different peptide analogs interact with receptor systems involved in endocrine regulation.
Scientific literature surrounding CJC-1295 and Ipamorelin focuses primarily on:
Research in these areas contributes to the broader scientific understanding of peptide-based signaling molecules and their interaction with receptor pathways studied in laboratory environments.
Research involving CJC-1295 and Ipamorelin can be found within scientific literature databases and peer-reviewed journals including:
Reviews
There are no reviews yet.
Only logged in customers who have purchased this product may leave a review.